Hale David F 的 Form 4 申報
Dermata Therapeutics, Inc.（DRMA），2021/8/17 申報
- 申報編號
- 0000905718-21-001110
- 申報時間
- 2021/8/17
- 交易日
- 2021/8/17
- 申報延遲
- 當天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
這份申報列了 6 筆非衍生性交易、8 筆衍生性交易。交易當天就申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Hale David FCIK 0001024004 | 董事、持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2021/8/17 | Common Stock | C轉換取得 | +44,777 | –F1 | – | 299,411 | 間接 | |
| 2021/8/17 | Common Stock | C轉換取得 | +12,195 | –F2 | – | 311,606 | 間接 | |
| 2021/8/17 | Common Stock | C轉換取得 | +20,000 | –F3 | – | 331,606 | 間接 | |
| 2021/8/17 | Common Stock | C轉換取得 | +174,216 | –F4 | – | 505,822 | 間接 | |
| 2021/8/17 | Common Stock | C轉換取得 | +27,103 | –F5 | – | 532,925 | 間接 | |
| 2021/8/17 | Common Stock | P買進取得 | +35,714 | –F8 | – | 35,714 | 間接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2021/8/17 | Common Stock | C轉換處分 | −44,777 | $0.00 | $0 | 0 | 間接 | |
| 2021/8/17 | Common Stock | C轉換處分 | −12,195 | $0.00 | $0 | 0 | 間接 | |
| 2021/8/17 | Common Stock | C轉換處分 | −20,000 | $0.00 | $0 | 0 | 間接 | |
| 2021/8/17 | Common Stock | C轉換處分 | −174,216 | $0.00 | $0 | 0 | 間接 | |
| 2021/8/17 | Common Stock | C轉換處分 | −27,103 | $0.00 | $0 | 0 | 間接 | |
| 2021/8/17 | Common Stock | C轉換處分 | −3,048 | $0.00 | $0 | 0 | 間接 | |
| 2021/8/17 | Common Stock | C轉換取得 | +3,048 | $0.00 | $0 | 3,048 | 間接 | |
| 2021/8/17 | Common Stock | P買進取得 | +35,714 | –F8 | – | 35,714 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date.
表 I 有 1 筆交易的價格引用這則附註。
- F2
The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date.
表 I 有 1 筆交易的價格引用這則附註。
- F3
The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date.
表 I 有 1 筆交易的價格引用這則附註。
- F4
The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date.
表 I 有 1 筆交易的價格引用這則附註。
- F5
The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date.
表 I 有 1 筆交易的價格引用這則附註。
- F8
Reporting Person purchased 35,714 Units in the IPO at $7.00 per Unit. Each Unit consists of one share of Common Stock and one warrant to purchase one share of Common Stock.
表 I 有 1 筆、表 II 有 1 筆交易的價格引用這則附註。